Haizheng pharmaceutical and celsion sign a memorandum of understanding to continue to promote thermodox

Haizheng pharmaceutical announced in the evening of July 19 that on July 19, the company signed a memorandum of understanding with celsion company of the United States to continue to promote the clinical research and technology transfer of thermodox (thermosensitive adriamycin liposome) for the commercial production of thermodox? In China, Hong Kong and Macao The MOU will clarify the specific objectives of technology transfer cooperation between the two sides, and the scope of cooperation will be extended to the development of new generation liposome formulation technology Haizheng pharmaceutical signed a long-term commercial supply agreement for its patented thermodox product with celsion in May 2012 In January 2013, the two sides signed another technical cooperation agreement on thermodox? Haizheng Pharmaceutical Co., Ltd paid a lump sum of US $5 million for research and development to celsion, which provided technology transfer for the production and research and development of thermodox On January 31, 2013, celsion announced that thermodox? Combined with radiofrequency ablation in the phase III clinical study (heat study) of primary liver cancer did not reach the main clinical study end point According to the latest memorandum of understanding signed on August 19, celsion company will provide the transfer of the first and second generation technology of thermosensitive liposome of Haizheng pharmaceutical, including the package of thermosensitive liposome technology applied to other products, and authorize the company to use relevant patents for product research and development and production free of charge Based on the subgroup analysis data provided by celsion and the results of FDA communication, Haizheng pharmaceutical will further discuss the clinical and registration plan of thermodox? In China with celsion Zhejiang Haizheng Pharmaceutical Co., Ltd and all members of the board of directors guarantee the authenticity, accuracy and completeness of the announcement, and shall be jointly and severally liable for the false records, misleading statements or major omissions of the announcement Zhejiang Haizheng Pharmaceutical Co., Ltd (hereinafter referred to as "the company") and American celsion company (hereinafter referred to as "celsion company") signed a long-term commercial supply agreement for its patented product thermodox (thermosensitive adriamycin liposome) in May 2012 In January 2013, the two sides signed a technical cooperation agreement on thermodox The company paid a lump sum of US $5 million for research and development to celsion, which provided technology transfer for thermodox production and research and development On January 31, 2013, celsion announced that thermodox combined with radiofrequency ablation in the phase III clinical study (heat study) of primary liver cancer did not reach the main clinical study end point Relevant announcements have been published in China Securities Journal, Shanghai Securities Journal, securities times and website of Shanghai Stock Exchange (www.sse Com CN) on May 8, 2012, January 23, 2013 and February 1, 2013 On July 19, 2013, the company and celsion signed a memorandum of understanding to continue to promote the clinical research and transfer of thermodox technology for the commercial production of thermodox in China, Hong Kong and Macao The MOU will clarify the specific objectives of technology transfer cooperation between the two sides, and the scope of cooperation will be extended to the development of new generation liposome formulation technology Celsion company will provide the transfer of the first and second generation technology of thermal liposome of the company, including the package of thermal liposome technology applied to other products, and authorize the company to use relevant patents for product research and development and production free of charge Based on the subgroup analysis data provided by celsion and the results of FDA communication, the company will further discuss with celsion about the clinical and registration plan of thermodox in China in the future Both sides will continue to work on the clinical research and registration of thermodox and other thermosensitive liposome products in China, and actively promote the commercialization of thermodox in China The company will be the first partner of thermodox's distribution right in Greater China to obtain the marketing right license in priority The company will disclose the progress in a timely manner in accordance with the relevant provisions of the Listing Rules of Shanghai Stock Exchange 1 Please make rational investment and pay attention to the investment risks It is hereby announced The board of directors of Zhejiang Haizheng Pharmaceutical Co., Ltd July 20, 2013